Link Pharma Chem GST demand cut to ₹16.3 lakh for FY22
- GST Appellate Authority reduced Link Pharma Chem's FY22 tax demand to ₹16.3 lakh
- Penalty amount decreased from ₹13.29 lakh to ₹2.05 lakh following the order
- Dispute centered on GSTR1-GSTR3B mismatches and excess ITC on imports
- Company plans to appeal the remaining liability despite reduced impact

*this image is generated using AI for illustrative purposes only.
Link Pharma Chem received an order from the GST Appellate Authority in Vadodara on October 12, 2026, significantly reducing its tax liability for the fiscal year 2021-22. The final demand was slashed from ₹1,32,94,322 to ₹16,29,852, while the associated penalty decreased from ₹13,29,433 to ₹2,05,605.
The regulatory filing disclosed that the initial dispute arose from alleged mismatches between tax liabilities declared in GSTR1 and payments made through GSTR3B. Additionally, authorities cited excess Input Tax Credit (ITC) availed on the import of goods that was not reflected in GSTR-2A.
Regulatory disclosure details
The company submitted this information under Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The order was issued by the GST Appellate Authority, Tribunal Vadodara.
| Particulars | Details |
|---|---|
| Authority | GST Appellate Authority, Tribunal Vadodara |
| Original Demand | ₹1,32,94,322 |
| Revised Demand | ₹16,29,852 |
| Original Penalty | ₹13,29,433 |
| Revised Penalty | ₹2,05,605 |
| Period | FY22 |
Financial impact and next steps
Link Pharma Chem stated that while the financial impact is limited to the revised demand, penalty, and interest amounts, there is no material impact on the company's operations or financial position. Despite the reduction, the company intends to file an appeal with the appropriate authority regarding the remaining liability.
What the numbers show
The appellate order resulted in a reduction of over 87% in the principal tax demand and nearly 85% in the penalty amount. This substantial decrease suggests the authority found significant merit in the company's defense against the initial claims of ITC mismatches and reporting discrepancies.
Historical Stock Returns for Link Pharma Chem
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | +3.49% | +3.17% | -5.86% | -23.92% | -28.48% |
How might Link Pharma Chem's decision to appeal the remaining liability affect its short-term cash flow and provision for contingent liabilities?
Will this favorable appellate ruling influence the tax audit strategies or compliance protocols of other pharmaceutical companies facing similar GSTR-1 and GSTR-3B mismatches?
Does the significant reduction in penalties suggest a shift in the GST Appellate Authority's interpretation of Input Tax Credit discrepancies for importers in the chemical sector?

































